| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- GOOBARLARSSON, L, et al.
(författare)
-
ENHANCEMENT OF HIV-1 PROTEINASE ACTIVITY BY HIV-1 REVERSE-TRANSCRIPTASE
- 1995
-
Ingår i: VIROLOGY. - : ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS. - 0042-6822. ; 206:1, s. 387-394
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- HIV-1 reverse transcriptase (RT) was found to increase the activity of HIV-I proteinase in vitro and in eukaryotic cells. The effect of RT on proteinase activity was dose-dependent and independent of pH or salt concentration. The cleavage of sequences cor
|
|
| 5. |
- Joelson, T, et al.
(författare)
-
Presentation of a foreign peptide on the surface of tomato bushy stunt virus
- 1997
-
Ingår i: JOURNAL OF GENERAL VIROLOGY. - : SOC GENERAL MICROBIOLOGY. - 0022-1317. ; 78, s. 1213-1217
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- A 13-amino-acid peptide derived from the V3 loop of human immunodeficiency virus (HIV-1) glycoprotein 120 (gp120) was attached as a C-terminal gene fusion to the coat protein of tomato bushy stunt virus (TBSV). The architecture of this plant virus permitt
|
|
| 6. |
- JURIMAE, T, et al.
(författare)
-
A SEMIEMPIRICAL STUDY OF HETEROCYCLE OLIGOMERS AND POLYMERS IN DIFFERENT DIELECTRIC MEDIA
- 1995
-
Ingår i: INTERNATIONAL JOURNAL OF QUANTUM CHEMISTRY. - 0020-7608. ; 54:6, s. 369-379
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- Four common five-membered heterocycles-pyrrole, phosphole, thiophene, and furan- and their oligomers with the chain length of 2, 4, 6, and 10 units have been studied quantum chemically using the semiempirical PM3 parameterization. The oligomers of pyrrole
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
- Strandberg, LE, et al.
(författare)
-
Anticoagulant effects of low-molecular-weight heparin following thrombolytic therapy in acute myocardial infarction: a dose-finding study
- 1996
-
Ingår i: Haemostasis. - : S. Karger AG. - 0301-0147. ; 26:5, s. 247-257
-
Tidskriftsartikel (refereegranskat)abstract
- The aim of the present study was to gain clinical experience with different dose levels of dalteparin, a low-molecular-weight heparin, following thrombolytic therapy in acute myocardial infarction. Compared to heparin, dalteparin has a longer half-life and a greater and highly predictable bioavailability, which would suggest dalteparin to be a convenient alternative. Twenty patients with ECG signs of acute transmural myocardial ischemia received streptokinase (1.5 million IU for 60 min) and were allocated to a control group or to open treatment with 50, 75 or 100 IU of dalteparin/kg b.w. s.c. b.i.d., starting 4 h later, for 6 days. Each group consisted of 5 patients. Except for the control group, aspirin was withheld during dalteparin treatment. Anti-factor-Xa (anti-FXa) values increased dose-dependently during the first 24 h and were maintained throughout the study period. On day 6, anti-FXa levels after 100 IU/kg b.w. were 0.79 (0.59-1.00) IU/ml (median, min.-max.) 4 h after administration of dalteparin, and 0.51 (0.34-0.82) IU/ml before the subsequent dose of dalteparin. In conclusion, our results indicate that a dalteparin dose slightly higher than 100 IU/kg b.w. is required in order to obtain the presumed therapeutic range of anti-FXa (0.6-1.0 IU/ml).
|
|
| 10. |
|
|
